(CUE) – Globe Newswire
-
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
-
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
-
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
-
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
-
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
-
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
-
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
-
Cue Biopharma to Host Investor Call
-
Cue Biopharma to Host Investor Call
-
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
-
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncolo
-
Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
-
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
-
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
-
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
-
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
-
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
-
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
-
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
-
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
-
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
-
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
-
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
-
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
-
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
-
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
-
Cue Biopharma to Present at Two February 2023 Scientific Conferences
-
Cue Biopharma to Present at Two February 2023 Scientific Conferences
-
Cue Biopharma Announces Chief Medical Officer Transition
-
Cue Biopharma Announces Chief Medical Officer Transition
-
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
-
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
-
Cue Biopharma Reports Third Quarter 2022 Financial Results
-
Cue Biopharma Reports Third Quarter 2022 Financial Results
-
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
-
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
-
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Ca
-
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Ca
-
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
Back to CUE Stock Lookup
